Orchid Pharma Reports Strong Q2 FY27 Results and Expansion
Orchid Pharma Ltd · Investor Presentation · 17 Nov 2026, 12:22 am
Orchid Pharma Reports Strong Q2 FY27 Results and Expansion Orchid Pharma delivered standalone revenue of ₹341 Cr for Q2 FY27, up 14% YoY, with EBITDA surging 148% YoY to ₹52 Cr as margins expanded to 15%. Consolidated PAT reached ₹28.59 Cr compared to a net loss of ₹0.90 Cr in Q2 FY26. For H1 FY27, consolidated operating cash flow stood at ₹117.78 Cr. Growth initiatives advanced with the amalgamation of Dhanuka Laboratories effective 10th Jul'26, EXBLIFEP licensing partnerships securing $258M in estimated potential across 10 markets, and ongoing CWIP on 7ACA and Cefiderocol projects.
Original exchange filing (PDF)
More announcements from Orchid Pharma Ltd
- Audio Recording of the Analysts/Investors Earnings Call - Orchid Pharma Limited ('the Company') · 18 Nov 2026
- Board Comments on fine levied by Stock Exchanges · 17 Nov 2026
- Statement of deviation or variation for the quarter ended on September 30, 2026 on the use of proceeds of funds raised through Qualified institutional placement (QIP) · 14 Nov 2026
- Declaration of Financial results for quarter and half year ended on September 30, 2026 · 14 Nov 2026
- Outcome of Board Meeting · 14 Nov 2026
- Orchid Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. · 14 Nov 2026
- Monitoring Agency Report for the Quarter-II ended on September 30, 2026 · 14 Nov 2026
- Intimation of schedule of Analysts/ Investors Earning Call for the Ouarter-II of F.Y. 2026-27 ended on September 30, 2026 · 17 Nov 2026
